In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011)

Journal of Global Antimicrobial Resistance

Volumn 2, Issue 3, 2014, Pages 183-189

  Flamm, Robert K ^a   Jones, Ronald N ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Meticillin resistant Staphylococcus aureus; Streptococcus pneumoniae; Surveillance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN DERIVATIVE; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE;

EID: 84906791783     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2014.02.006     Document Type: Article

References (21)

1. European Medicines Agency. Assessment report for Zinforo (ceftaroline fosamil) Procedure No. EMEA/H/C/002252. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Public-assessment-report/human/002252/WC500132587.pdf [accessed 29.08.13].
2. Forest Laboratories, Inc. Teflaro® package insert. Forest Laboratories, Inc.; 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2013/200327s009lbl.pdf [accessed 29.08.13].
3. D. Biek, I.A. Critchley, T.A. Riccobene, and D.A. Thye Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity J Antimicrob Chemother 65 Suppl. 4 2010 iv9 iv16
4. I.A. Critchley, P.B. Eckburg, A. Jandourek, D. Biek, H.D. Friedland, and D.A. Thye Review of ceftaroline fosamil microbiology: integrated FOCUS studies J Antimicrob Chemother 66 Suppl. 3 2011 iii45 iii51
5. H. Moisan, M. Pruneau, and F. Malouin Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae J Antimicrob Chemother 65 2010 713 716
6. K. Kosowska-Shick, P.L. McGhee, and P.C. Appelbaum Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae Antimicrob Agents Chemother 54 2010 1670 1676
7. T.M. File Jr., M.H. Wilcox, and G.E. Stein Summary of ceftaroline fosamil clinical trial studies and clinical safety Clin Infect Dis 55 Suppl. 3 2012 S173 S180
8. D.R. Rank, H.D. Friedland, and J.B. Laudano Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia J Antimicrob Chemother 66 Suppl. 3 2011 iii53 iii59
9. G.R. Corey, M. Wilcox, G.H. Talbot, H.D. Friedland, T. Baculik, and G.W. Witherell et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
10. D.J. Farrell, M. Castanheira, R.E. Mendes, H.S. Sader, and R.N. Jones In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008-2010) Clin Infect Dis 55 Suppl. 3 2012 S206 S214
11. D.J. Farrell, R.K. Flamm, H.S. Sader, and R.N. Jones Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010) Int J Antimicrob Agents 41 2013 337 342
12. R.K. Flamm, H.S. Sader, D.J. Farrell, and R.N. Jones Summary of ceftaroline activity against pathogens in the United States 2010. Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program Antimicrob Agents Chemother 56 2012 2933 2940
13. R.N. Jones, D.J. Farrell, R.E. Mendes, and H.S. Sader Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study J Antimicrob Chemother 66 Suppl. 3 2011 iii69 iii80
14. R.N. Jones, R.E. Mendes, and H.S. Sader Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study J Antimicrob Chemother 65 Suppl. 4 2010 iv17 iv31
15. J.A. Karlowsky, H.J. Adam, M.R. Decorby, P.R. Lagace-Wiens, D.J. Hoban, and G.G. Zhanel In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients attending Canadian hospitals in 2009 Antimicrob Agents Chemother 55 2011 2837 2846
16. M.A. Pfaller, D.J. Farrell, H.S. Sader, and R.N. Jones AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States Clin Infect Dis 55 Suppl. 3 2012 S187 S193
17. H.S. Sader, R.K. Flamm, D.J. Farrell, and R.N. Jones Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients: AWARE Ceftaroline Surveillance Program Clin Infect Dis 55 Suppl. 3 2012 S181 S186
18. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Document M07-A9 9th ed. 2012 CLSI Wayne, PA
19. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. Document M100-S23 2013 CLSI Wayne, PA
20. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. http://www.eucast.org/clinical-breakpoints/ [accessed 02.01.13].
21. Wyeth Pharmaceuticals Inc. Tygacil® package insert 2011 Wyeth Pharmaceuticals Inc. http://www.tygacil.com [accessed 02.01.13]